hat
Enobosarm, pli enkoni ke kòm Ostarine oubyen MK, 2866, se yon Sélectif monn mal Récepteurs Modilatè (SARM) devlope pa GTx (GTx-024) pou konbat gaspiye doulè misk ak osteyopowoz va ogmante tou. Anpil yo pwedi Ostarine ka jwenn itilize nan monn ranplasman tretman plan, tou nan tretman sarcopenia, cachexia ak doulè misk fennen. Sa se yon trè pwesye benefis pou moun soufwi ak doulè misk gaspiye maladi, plis se konsa paske SARM’s te montre pou pa gen yon enpak sou misk ki pa-skèlèt.
eng
Enobosarm, better known as as Ostarine or MK 2866, is a Selective Androgen Receptor Modulator (SARM) developed by GTx (GTx-024) to combat muscle wasting and osteoporosis. Many speculate Ostarine may find uses in hormone replacement treatment plans, as well as in the treatment of sarcopenia, cachexia and muscle atrophy. This is a highly valuable benefit to those suffering from muscle wasting diseases, more so because SARM’s have been shown to not have an impact on non-skeletal muscle.